NCT04041843View on ClinicalTrials.gov

Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 2, 2017

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2022

Conditions
Venous Thromboembolism
Interventions
DRUG

Apixaban

Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg

Trial Locations (1)

10595

New York Medical College, Valhalla

Sponsors
All Listed Sponsors
lead

New York Medical College

OTHER

NCT04041843 - Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism | Biotech Hunter | Biotech Hunter